< Back to previous page
Researcher
Isabelle Huys
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Responsible
From17 Dec 2020 → Today - Faculty of Law and Criminology (Faculty)
Member
From1 Oct 2014 → 30 Sep 2015 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today - Toxicology and Pharmacology (Division)
Member
From1 Oct 1999 → 9 Mar 2004
Projects
1 - 10 of 50
- Collaborative licensing models for marine genetic resources in striving for efficient, accessible and equitable management of intellectual property rightsFrom12 Feb 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- How to create sustainable market access to advanced therapies?From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Organoid technologies for disease modeling, drug discovery and development for rare diseasesFrom1 Jan 2024 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Sustainable COVID-19 Vaccination for Long-term Vaccine Immunity and EffectivenessFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Does patient empowerment foster access to and re-use of data in biomedical research, while allowing for meaningful protection of the fundamental right to data protection of patients?From1 Nov 2023 → TodayFunding: FWO junior postdoctoral fellowship
- What are the key factors needed for potential valorization of Marine Natural Products (MNPs)?From1 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Stakeholder Perspectives on Gene Therapy in CardiomyopathyFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Shared decision-making for lung cancer prevention: patient-driven development and evaluation of a decision aid for patients and healthcare providersFrom11 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Shared decision-making for lung cancer prevention: patient-driven development and evaluation of a decision aid for patients and healthcare providersFrom1 Sep 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Patient Experience Data for Innovative TherapiesFrom31 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 213
- Testing and Practical Implementation of a User-Friendly Personalized and Long-Term Electronic Informed Consent Prototype in Clinical Research: Mixed Methods Study(2023)
Authors: David Geerts, Koen Yskout, Stef Verreydt, Pascal Borry, Liese Barbier, Isabelle Huys
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market Sustainability(2023)
Authors: Teresa Barcina Lacosta, Steven Simoens, Isabelle Huys
- A Belgian policy framework for best-value biological medicines(2023)
Authors: Yannick Vandenplas, Isabelle Huys, Steven Simoens, Arnold Vulto
- Balancing Innovation With Optimization in Oncology: Avenues for Bridging the Cancer Clinical Research Gap(2023)
Authors: Robbe Saesen, Isabelle Huys
- Cross-border clinical research in the EU: Fair allocation of data control and responsibility(2023)
Authors: Teodora Lalova-Spinks, Isabelle Huys, Peggy Valcke
- How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action(2023)
Authors: Rosanne Janssens, Liese Barbier, Elise Schoefs, Isabelle Huys
- The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis(2023)
Authors: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- Development of Cell and Gene Therapy Products: Implementation of a Blended Learning Approach(2023)
Authors: Isabelle Huys
Pages: 611 - 611 - Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments(2023)
Authors: Robbe Saesen, Isabelle Huys
- Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives(2023)
Authors: Rosanne Janssens, Elise Schoefs, Kristiaan Nackaerts, Isabelle Huys